Selinski et al. (2013[60]) reported that the ultra-slow NAT2 status increases the risk of urinary bladder cancer even if the classic slow NAT2 acetylation status, which includes all genotypes coding for a slow NAT2 acetylation status, no longer shows an increased risk of urinary bladder cancer. This evidence concerns the gene NAT2 and urinary bladder cancer.